← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
sofosbuvir, velpatasvir and voxilaprevir
J05AP56
Forms & Strengths
- Tablets: sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg
- Fixed-dose combination
Adult Dosing
- 1 tablet orally once daily with food
- Recommended treatment duration: 8, 12, or 16 weeks depending on patient population and HCV genotype
- Dose adjustment not required for mild, moderate or severe renal impairment
- Dose adjustment not required for mild hepatic impairment, use with caution in moderate hepatic impairment
- Contraindicated in severe hepatic impairment
Pediatric Dosing
- Safety and efficacy not established in patients less than 18 years of age
Indications
- Treatment of chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis
- Genotypes 1, 2, 3, 4, 5, or 6
- Treatment of HCV infection in adult liver transplant recipients without cirrhosis or with compensated cirrhosis
Mechanism of Action
- Sofosbuvir: nucleotide analog NS5B polymerase inhibitor
- Velpatasvir: NS5A inhibitor
- Voxilaprevir: NS3/4A protease inhibitor
- Inhibition of HCV replication
Contraindications
- Severe hepatic impairment
- Concomitant use with ribavirin in pregnant women or male partners of pregnant women
Adverse Reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
- Serum liver enzyme elevations
Drug Interactions
- Amiodarone: serious symptomatic bradycardia when co-administered with sofosbuvir
- Anticonvulsants: decreased sofosbuvir and velpatasvir concentrations
- P-glycoprotein inducers: decreased voxilaprevir concentrations
- HMG-CoA reductase inhibitors: increased risk of myopathy
Curated Content: Needs Vetting Before Put to Clinical Use